observed, in 113 patients with diffuse large B-cell lymphoma (DLCBL) receiving standard therapy, that significantly higher complete (CR) and overall response rates (ORR) were associated with the FcγRIIIa-158V/V genotype, compared with FcγRIIIa-158V/F or F/F (CR: 88% in V/V vs 79% in V/F vs 50% in F/F; ORR: 98% in V/V vs 90% in V/F vs 50% in F/F; p=0.002) (15). This evidence concerns the gene FCGR3A and diffuse large B-cell lymphoma.